Vannes

• MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending
  2024-513889-19-00 5 Multiple Myeloma
• Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplas … Pending
  2024-515362-13-00 10 Philadelphia-negative myeloproliferative neoplasms are frequent and ch
• LIDOCRIT : Effect of continuous intravenous LIDOCaine on discomfort in postoperative CRITical care inpatients Pending
  2024-517749-15-00 11 Postoperative critical care
• Postoperative anti-infective strategy following pancreaticoduodenectomy in patients with preoperative biliary stent FRENCH24 ANIS Recruiting
  2024-515181-14-00 5 2026-05-20 Patients with preoperative biliary stent treated by pancreaticoduodene
• COLCOT-T2D Recruiting
  2024-516646-19-00 5 2025-08-15 Type 2 diabetic patients with no prior cardiovascular (CV) events
• ENGIC 02 - PRODIGE 86-FOLFIRINOX SBA- Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanc … Recruiting
  2023-505486-92-00 4 2024-02-09 Small bowel adenocarcinoma
• A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethaso … Recruiting
  2024-511855-16-00 5 2019-07-25 Onco-hematology
• PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting
  2023-505046-26-00 5 2026-05-07 Colon carcinoma
• Apneic oxygenation with high-flow nasal oxygenation after preoxygenation with noninvasive ventilation before intubation in hypoxemic patient … Recruiting
  2024-514949-11-00 5 2026-03-18 Hypoxemic acute respiratory failure
• A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratum … Recruiting
  2025-520897-21-00 10 2026-02-25 Multiple Myeloma
• FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients prev … Recruiting
  2023-505781-28-00 4 2026-01-20 Patients with Waldenstrom macroglobulinemia and have received at least
• Dapagliflozine for cardio-renal protection at ICU discharge Recruiting
  2024-510941-32-00 5 2025-12-02 Adult patients discharged alive from ICU with a decreased eGFR, and/or
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i … Recruiting
  2024-518365-10-00 5 2025-10-28 Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
• Digital monitoring of self-reported symptoms by patients treated with Cabozantinib plus Nivolumab for advanced clear-cell renal carcinoma: T … Recruiting
  2024-518991-30-00 6 2025-07-17 kidney cancer
• A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf … Recruiting
  2024-516418-39-00 5 2025-07-09 Multiple Myeloma
• IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as p … Recruiting
  2024-517325-43-00 4 2025-06-19 multiple myeloma
• Corticodependent or corticoresistant brain radionecrosis after radiotherapy for brain metastases: a multicentre randomized, controlled doub … Recruiting
  2024-510893-25-00 5 2025-04-29 Brain metastases of cancer > brain radionecrosis
• Safety and efficacy of apixaban versus warfarin in peritoneal dialysis patients with non valvular atrial fibrillation: a randomized controll … Recruiting
  2023-507544-37-00 5 2025-01-08 patients with end-stage renal disease on chronic peritoneal dialysis a
• Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiorit … Recruiting
  2024-510981-18-00 5 2024-12-12 Multiple Myeloma Multiple myeloma (MM) is a B cell malignancy and is o
• FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting
  2024-515300-39-00 4 2024-10-18 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF G
• RIVACAST - RIVAroxaban versus low-molecular weight heparin in patients with lower limb trauma requiring brace or CASTing Recruiting
  2023-509905-62-00 5 2024-07-19 Lower limb trauma requiring immobilisation
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C … Recruiting
  2023-507407-59-00 5 2024-07-04 Chronic Obstructive Pulmonary Disease (COPD)
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 Untreated FLIPI 2-5 Follicular Lymphoma
• C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL … Recruiting
  2023-507871-23-00 5 2024-05-27 Relapsed/Refractory Multiple Myeloma

Showing 1–24 of 56 trials